Feng Min, Tang Chengwu, Feng Wenming, Bao Ying, Zheng Yinyuan, Shen Jianbin
Department of General Surgery.
Department of Radiology, First People's Hospital, Huzhou University Medical College, Huzhou, Zhejiang, China.
Onco Targets Ther. 2017 Jun 14;10:3001-3005. doi: 10.2147/OTT.S136806. eCollection 2017.
To evaluate the effect of postoperative hepatic artery-infusion chemotherapy (HAIC) on survival probability in patients with hepatocellular carcinoma (HCC) after radical hepatectomy.
This retrospective study included 85 patients with HCC who received radical hepatectomy from May 2005 to May 2010. Among these patients, 42 underwent two sessions of HAIC (5-fluoruracil [1,000 mg/m], oxaliplatin [85 mg/m], and mitomycin-C [6 mg/m]) after radical hepatectomy (HAIC group), and 43 underwent radical hepatectomy only (the control group). HAIC-related side effects and long-term survival were retrospectively analyzed.
The HAIC group showed a significantly higher 5-year intrahepatic recurrence-free survival probability and lower risk of intrahepatic recurrence (HR 0.5615, 95% CI 0.3234-0.9749 [log-rank test]; =0.0332). The HAIC group also had significantly higher 5-year disease-free survival probability (HR 0.591, 95% CI 0.3613-0.9666 [log-rank test]; =0.0298) and overall survival probability than the control group (HR 0.5768, 95% CI 0.3469-0.9589 [log-rank test]; =0.0278). No HAIC-related deaths in the HAIC group were reported. All toxicities and complications were controlled, and no patients quit the treatment.
HAIC can effectively and safely reduce intrahepatic recurrence and improve the long-term survival of patients with HCC after radical hepatectomy.
评估术后肝动脉灌注化疗（HAIC）对肝细胞癌（HCC）患者根治性肝切除术后生存概率的影响。
本回顾性研究纳入了2005年5月至2010年5月期间接受根治性肝切除的85例HCC患者。其中，42例患者在根治性肝切除术后接受了两个疗程的HAIC（5-氟尿嘧啶[1,000 mg/m]、奥沙利铂[85 mg/m]和丝裂霉素-C[6 mg/m]）（HAIC组），43例仅接受了根治性肝切除（对照组）。对HAIC相关的副作用和长期生存情况进行了回顾性分析。
HAIC组的5年肝内无复发生存概率显著更高，肝内复发风险更低（HR 0.5615，95%CI 0.3234 - 0.9749[对数秩检验]；P = 0.0332）。HAIC组的5年无病生存概率也显著高于对照组（HR 0.591，95%CI 0.3613 - 0.9666[对数秩检验]；P = 0.0298），总生存概率也高于对照组（HR 0.5768，95%CI 0.3469 - 0.9589[对数秩检验]；P = 0.0278）。HAIC组未报告与HAIC相关的死亡病例。所有毒性反应和并发症均得到控制，无患者退出治疗。
HAIC可有效、安全地降低肝内复发，提高HCC患者根治性肝切除术后的长期生存率。
